Contrast developer Guerbet is launching a multiuse version of its OptiVantage syringe-based injector at RSNA 2018 in Chicago.
The injector is used to administer contrast agents for CT scans, and the new version is adapted to multiuse markets and is available in pedestal and ceiling-mount versions.
The new multiuse/patient version includes the Opti-Vantage syringe-based injector; a complete range of associated syringes and disposables, including the manyFill day set and secufill patient line; services, and the support system of OptiProtect.
Customers already using the injector may request an upgrade to get the multiuse version, according to the company.
Guerbet also announced that multiuse OptiVantage has received the CE Mark in Europe, paving the way for launch in that region in January.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)